Long Term Beta Thalassemia Treatment: Findings From The Extension Period

The project, titled "Long Term Beta Thalassemia Treatment: Findings From The Extension Period Of Phase 2 Clinical Trial," aims to compare the efficacy and safety of combination therapy (thalidomide and hydroxyurea) versus thalidomide alone. The study, lasting three years, is a Phase 2 single-center, open-label interventional study with a sample size of 30 participants aged 8-35 years. It includes specific inclusion and exclusion criteria for participant selection. Data will be collected through clinical interviews and medical records and analyzed using(Statistical Package for the Social Sciences. This project aims to enhance beta thalassemia treatment strategies, focusing on reducing transfusion dependency and improving patient quality of life.

NCT Number	NCT06490601
Lead Sponsor	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Conditions	Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies
Enrollment	30 participants
Start Date	2022-04-01
Primary Completion	2024-04-01 (estimated)
Study Completion	2025-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-30